CRMD Stock Overview
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CorMedix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.57 |
| 52 Week High | US$13.85 |
| 52 Week Low | US$2.89 |
| Beta | 1.53 |
| 1 Month Change | -13.96% |
| 3 Month Change | 17.40% |
| 1 Year Change | 128.53% |
| 3 Year Change | 72.09% |
| 5 Year Change | 20.03% |
| Change since IPO | -42.87% |
Recent News & Updates
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark
Dec 13
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns
Nov 14Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Nov 04CorMedix 2.0: New Leadership, New Approval, New Focus
Oct 28CorMedix: Delayed Approval, Low Cash, Good Prospects
Oct 19Recent updates
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark
Dec 13Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns
Nov 14Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Nov 04CorMedix 2.0: New Leadership, New Approval, New Focus
Oct 28CorMedix: Delayed Approval, Low Cash, Good Prospects
Oct 19We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Sep 30We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Apr 06We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Nov 02Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 31CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
Feb 25FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%
Aug 08Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 16We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Mar 01Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Sep 09CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price
Feb 11We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely
Jan 04Shareholder Returns
| CRMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.3% | -1.6% | -2.4% |
| 1Y | 128.5% | 7.8% | 23.3% |
Return vs Industry: CRMD exceeded the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: CRMD exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| CRMD volatility | |
|---|---|
| CRMD Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRMD's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 83 | Joe Todisco | www.cormedix.com |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. Fundamentals Summary
| CRMD fundamental statistics | |
|---|---|
| Market cap | US$520.00m |
| Earnings (TTM) | -US$46.15m |
| Revenue (TTM) | US$12.26m |
42.4x
P/S Ratio-11.3x
P/E RatioIs CRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRMD income statement (TTM) | |
|---|---|
| Revenue | US$12.26m |
| Cost of Revenue | US$2.01m |
| Gross Profit | US$10.25m |
| Other Expenses | US$56.40m |
| Earnings | -US$46.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 83.57% |
| Net Profit Margin | -376.35% |
| Debt/Equity Ratio | 0% |
How did CRMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CorMedix Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Edward White | FBR Capital Markets & Co. |
| Morris Ajzenman | Griffin Securities |